



Mr. Jeffrey Lacasse, MSW
Florida State University
College of Social Work
University Center "C" Room 2411
Tallahassee, FL 32306-2570

September 22, 2005

Jonathan Leo, Ph.D.
Co-Editor-in-Chief, *Ethical Human Psychology and Psychiatry*
Springer Publishing
New York, NY 10036

RE: Promotional materials for Adderall XR[®] CII Capsules

Dear Mr. Lacasse and Dr. Leo:

This letter responds to your August 1, 2005, complaint report to the Division of Drug Marketing, Advertising, and Communications (DDMAC) concerning a direct-to-consumer print advertisement for Adderall XR CII Capsules (Mixed Salts of a Single-Entity Amphetamine Product) Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Amphetamine Sulfate.

DDMAC is responsible for monitoring and regulating the promotion of prescription drugs. Some of our most important resources in monitoring the prescription drug market are health care professionals, such as you, who provide information and insight about the promotional practices of pharmaceutical manufacturers. Your complaint has been forwarded to the undersigned and we have determined that it raises interesting issues that will be carefully evaluated for further action.

Sincerely,

{See appended electronic signature page}

Jennifer C. Murphy, Pharm.D.
Consumer Promotion Analyst
Division of Drug Marketing,
Advertising, and Communications